

The listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

---

Claim 1 (Currently Amended): A method of compensating for an absolute or relative testosterone deficiency in a patient who has said testosterone deficiency with simultaneous prophylaxis in said patient for the development of a benign prostatic hyperplasia (BPH) or a prostate cancer comprising administering to said patient a combination of a natural or synthetic androgen, and a gestagen, an antigestagen, an antiestrogen, a GnRH analog, a testosterone-5 $\alpha$ -reductase inhibitor, an  $\alpha$ -andreno-receptor blocker or a phosphodiesterase inhibitor.

---

Claim 2 (previously amended): A method according to claim 1, wherein the natural androgen component is testosterone, testosterone undecanoate, dehydroepiandrosterone, dehydroepiandrosterone sulfate, testosterone propionate, testosterone enanthate, testosterone buciclate, testosterone cypionate or androstene dione.

Claim 3 (previously amended): A method according to claim 1, wherein the synthetic androgen component is 17-methyltestosterone, fluoxymesterone, danazol, mesterolone, nandrolone decanoate, nandrolone phenylpropionate, oxandrolone, oxymetholone, or stanazolol.

61 Claim 4 (previously amended): A method according to claim 1, wherein the gestagen component is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, a norethisterone ester, levonorgestrel, progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

Claim 5 (previously amended) A method according to claim 1, wherein the antigestagen component is

4-[17 $\beta$ -Hydroxy-17 $\alpha$ -(methoxymethyl)-3oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1(E)-oxime (J 912);

4-[-17 $\beta$ -methoxy-17 $\alpha$ -(methoxymethyl)-3-oxo-estra-4,9-dien-11 $\beta$ -yl]-benzaldehyde-1(E)-{O-[(ethylthio)carbonyl]}-oxime (J 1042);

4-[9 $\alpha$ ,10 $\alpha$ -epoxy-17 $\beta$ -hydroxy-17 $\alpha$ -(methoxymethyl)-3-oxo-estr-4-en-11 $\beta$ -yl]-benzaldehyde-1(E)-oxime (J 1116);

---

4-[17 $\beta$ -methoxy-17 $\alpha$ -(methoxymethyl)-3oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1(E)-oxime (J 867);

4-[17 $\beta$ -hydroxy-17 $\alpha$ -(methoxymethyl)-3oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1(E)-{O-[(N-ethyl)-carbonyl]}-oxime (J 956);

11 $\beta$ -[(4-N,N-dimethylamino)-phenyl]-17 $\beta$ -hydroxy-17 $\alpha$ -propinyl-estra-4,9-dien-3-one (RU 38 486 - mifepristone);

11 $\beta$ -[(4-N,N-dimethylamino)-phenyl]-17 $\alpha$ -hydroxy-17 $\beta$ -(3-hydroxypropyl)-13 $\alpha$ -methyl-gona-4,9-dien-3-one (ZK 98299 - onapristone);

11 $\beta$ -(4-acetylphenyl)-17 $\beta$ -hydroxy-17 $\alpha$ -propinyl-estra-4,9-dien-3-one (ZK 112993);

11 $\beta$ -[(4-N,N-dimethylamino)-phenyl]-17 $\beta$ -hydroxy-17 $\alpha$ -(3-hydroxy-1-(Z)-propenyl)-estra-4,9-dien-3-one (ZK 98 734 - lilopristone);

11 $\beta$ -[(4-N,N-dimethylamino)-phenyl]-17 $\beta$ -hydroxy-17 $\alpha$ -(3-hydroxy-1-(Z)-propenyl)-estra-4-en-3-one (ZK 137 316);

11 $\beta$ -[(4-N,N-dimethylamino)-phenyl]-6 $\beta$ -methyl-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3'H)-furan]-3-one (ORG 31 710);

11 $\beta$ -[(4-N,N-dimethylamino)-phenyl]-7 $\beta$ -methyl-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3'H)-furan]-3-one (ORG 31 806); or

11 $\beta$ -(4-acetylphenyl)-(3'E)-ethylidene-4',5'dihydrospiro-[estra-4,9-diene-17,2'(3H)-furan]-3-one (ORG 33 628).

---

Claim 6 (previously cancelled)

Claim 7 (previously amended): A method according to claim 1, wherein the GnRH-analog component is buserelin, goserelin, nafarelin, triptorelin or deslorelin, leuprolide or leuprolide acetate.

Claim 8 (previously amended): A method according to claim 1, wherein the antiestrogen component is tamoxifen, raloxifene, panomifene, toremifene, iproxifene or idoxifene.

Claim 9 (previously amended): A method according to claim 1, wherein the testosterone-5 $\alpha$ -reductase-inhibitor component is finasteride, epristeride, permixon, or turosteride.

Claim 10 (previously amended): A method according to claim 1, wherein the  $\alpha$ -andreno-receptor-blocker component is tolazoline, phentolamine, phenoxybenzamine, alfuzosin, or prazosin.

Claim 11 (previously amended): A method according to claim 1, wherein the phosphodiesterase-inhibitor component is amrinone, milrinone, trapidil, papaverine, vesnarinone or sildenafil.

Claim 12 (previously amended): A method of claim 1 wherein said combination is used in the form of a tablet, capsule, coated tablet, transdermal therapy system, ampoule, suppository, gel, ointment, nose drop, implant, pressed part or biodegradable microspheres.

---

Claim 13 (previously added): A method according to claim 2, wherein a gestagen is administered which is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, norethisterone acetate, levonorgestrel or progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

Claim 14 (previously added): A method according to claim 3, wherein a gestagen is administered which is dienogest, levonorgestrel, gestodene, desogestrel, norgestimate, norethisterone, norethisterone acetate, levonorgestrel or progesterone, chloromadinone acetate, cyproterone acetate, medroxy progesterone acetate, megestrol acetate, dydrogesterone, trimegestone or nomegestrol.

Claim 15 (previously added): A method of claim 4 wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 16 (previously added): A method of claim 13 wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 17 (previously added): A method of claim 14 wherein the dosage of androgen is 250-1500 mg i.m. every 4 to 14 weeks and the dosage of gestagen is 20 µg to 20 mg.

Claim 18 (previously added): A method according to claim 1, wherein said natural androgen is testosterone undecanoate.

Claim 19 (previously added): A method according to claim 1, wherein said natural androgen is testosterone enanthate.

---

Claim 20 (previously added): A method according to claim 1, wherein a gestagen is administered which is dienogest.

Claim 21 (previously added): A method according to claim 1, wherein a gestagen is administered which is a norethisterone ester.

Claim 22 (previously added): A method according to claim 1, wherein a gestagen is administered which is chloromadinone.

Claim 23 (previously added): A method according to claim 1, wherein a gestagen is administered which is cyproterone acetate.

Claim 24 (previously added): A method according to claim 1, wherein an antigestagen is administered which is 4-[17β-Hydroxy-17α-(methoxymethyl)-3oxoestra-4,9-dien-11β-yl]benzaldehyde-1(E)-oxime.

Claim 25 (previously added): A method according to claim 1, wherein an antigestagen is administered which is 4-[-17β-methoxy-17α-(methoxymethyl)-3-oxo-estra-4,9-dien-11β-yl]-benzaldehyde-1(E)-{O-[(ethylthio)carbonyl]}-oxime.

Claim 26 (previously added): A method according to claim 1, wherein an antigestagen is administered which is 4-[9 $\alpha$ ,10 $\alpha$ -epoxy-17 $\beta$ -hydroxy-17 $\alpha$ -(methoxymethyl)-3-oxo-estr-4-en-11 $\beta$ -yl]-benzaldehyde-1(E)-oxime.

Claim 27 (previously added): A method according to claim 1, wherein an antigestagen is administered which is 4-[17 $\beta$ -methoxy-17 $\alpha$ -(methoxymethyl)-3oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1(E)-oxime.

*Cancel*  
~~Claim 28 (previously added): A method according to claim 1, wherein an antigestagen is administered which is 4-[17 $\beta$ -hydroxy-17 $\alpha$ -(methoxymethyl)-3oxoestra-4,9-dien-11 $\beta$ -yl]benzaldehyde-1(E)-{O-[(N-ethyl)-carbonyl]}-oxime.~~

---